Yasir Tarabichi, MD
Pulmonary Disease · Cleveland, OHNPI 1790929453
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,575 of the $40,575 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Beckman Coulter, Inc.. Reporting peaked in 2021 at $24,375 and has fallen 78.5% since, to $5,250 in 2024. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $3381.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beckman Coulter, Inc.$41K
Across 8 payments — averaging $25,872 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beckman Coulter, Inc.$207K
What the payments were for
- Consulting fees$40,575100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beckman Coulter, Inc. | 12 | $40,575 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DXH 900$24,375
- DXH 900 Hematology System$4,725
How this compares
$40,575 in reported general payments places this provider in the 90th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva HandihalerTiotropium Bromide | 51 | $73,883 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $32,407 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $21,717 |
| DuleraMometasone/Formoterol | 25 | $20,428 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $19,638 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $16,196 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $13,637 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $13,051 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 46 | $12,172 |
| Tiotropium Bromide | 11 | $11,243 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $7,063 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $4,801 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 109 | $4,625 |
| Roflumilast | 17 | $1,608 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,100 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Cleveland
- Kristin HighlandCleveland$551K
- Joseph CiceniaCleveland$350K
- Michael MachuzakCleveland$286K
- Marie BudevCleveland$159K
- Leslie TolleCleveland$136K
- Elliott DasenbrookCleveland$114K
- James StollerCleveland$101K
- Gustavo Heresi DavilaCleveland$98K
- Bryan BennCleveland$96K
- Thomas GildeaCleveland$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.